Canine hepatitis etiology pathogenesis clinical signs diagnosis treatments and their managment from different books and with their tables
Reading File
search_medical_text
canine hepatitis etiology pathogenesis infectious canine hepatitis adenovirus
search_medical_text
canine hepatitis clinical signs diagnosis laboratory findings treatment management
GradeResponse
GradeResponse
Canine hepatitis (Infectious Canine Hepatitis, ICH)
Your request is veterinary and detailed, so here is a structured summary with tables covering:
- Etiology
- Pathogenesis
- Clinical signs
- Diagnosis
- Treatment and case management
Note: Retrieved tool content did not return useful canine specific veterinary textbook passages, so this answer is completed from standard veterinary medicine knowledge (small animal internal medicine/infectious disease references).
1) Etiology
Primary cause:
- Canine adenovirus type 1 (CAV-1), a non-enveloped DNA virus.
Transmission:
- Oro-nasal exposure to infected urine, feces, saliva.
- Indirect transmission via contaminated environment/fomites.
- Recovered dogs can shed virus in urine for months.
Risk groups:
- Unvaccinated puppies and young dogs.
- Dogs in high-density settings (shelters, kennels).
2) Pathogenesis
- Entry and initial replication in tonsils/lymphoid tissues.
- Viremia within a few days spreads virus systemically.
- Viral tropism for:
- Vascular endothelium -> vasculitis, edema, hemorrhage, DIC risk
- Hepatocytes -> acute hepatocellular necrosis
- Renal tissue -> prolonged urinary shedding
- Eye (uvea/cornea) during immune phase -> “blue eye” (corneal edema, immune-complex associated)
- Disease severity ranges from peracute fatal to mild/subclinical depending on age, immunity, and viral load.
3) Clinical signs
Typical signs
- Fever (often biphasic), depression, anorexia
- Vomiting, abdominal pain
- Hepatomegaly, icterus (variable)
- Petechiae/ecchymoses, prolonged bleeding (coagulopathy)
- Cervical edema, tonsillitis/pharyngitis
- Tachypnea (if pulmonary involvement/edema)
Ocular sign
- Corneal edema (“blue eye”), anterior uveitis in recovering phase
Hyperacute/peracute form
- Sudden collapse, shock, hemorrhage, death (especially in very young pups)
4) Diagnosis
Diagnosis is based on history + exam + labs + confirmatory testing.
Core diagnostic approach
- CBC, chemistry, urinalysis, coagulation profile
- Infectious confirmation: PCR (blood/tissues/secretions) where available
- Consider paired serology (less useful acutely than PCR)
- Necropsy/histopathology in fatal cases: hepatic necrosis with intranuclear inclusion bodies
Table: Expected findings in canine infectious hepatitis
| Category | Common findings |
|---|---|
| CBC | Leukopenia early; later variable leukogram; thrombocytopenia possible |
| Serum biochemistry | Marked ALT/AST increase, hyperbilirubinemia (variable), hypoglycemia in severe cases, hypoalbuminemia in advanced disease |
| Coagulation | Prolonged PT/aPTT, evidence of consumptive coagulopathy/DIC in severe disease |
| Urinalysis | Proteinuria/hematuria possible; virus may be shed in urine |
| Imaging (US) | Enlarged, hypoechoic or heterogeneous liver; free abdominal fluid in severe disease |
| Specific test | PCR for CAV-1 (preferred confirmatory test) |
| Pathology (if deceased) | Centrilobular to massive hepatic necrosis, endothelial damage, intranuclear inclusion bodies |
5) Treatment
There is no specific widely used antiviral for routine ICH; management is mainly aggressive supportive care.
Treatment principles
- IV crystalloids (careful perfusion support; avoid fluid overload)
- Correct hypoglycemia, electrolyte and acid-base disturbances
- Antiemetics, gastroprotection, early enteral nutrition when stable
- Hepatic support (case-based use; e.g., SAMe/silymarin adjuncts)
- Plasma/blood products if coagulopathy or significant bleeding
- Broad-spectrum antibiotics only when secondary bacterial infection risk is high (not for virus itself)
- Analgesia as needed (avoid hepatotoxic choices)
Table: Treatment and management plan by severity
| Severity | Typical status | Management |
|---|---|---|
| Mild | Fever, lethargy, mild GI signs, stable perfusion | Outpatient/inpatient observation, fluids as needed, antiemetic, nutritional support, monitor CBC/chem daily initially |
| Moderate | Persistent vomiting, dehydration, rising liver enzymes, early coagulopathy | Inpatient care, IV fluids, antiemetic + GI protectants, glucose/electrolyte correction, serial coagulation tests, consider plasma if clotting times worsen |
| Severe/critical | Hemorrhage, shock, DIC, encephalopathy, severe hepatic dysfunction | ICU-level care, aggressive hemodynamic stabilization, plasma/blood transfusion, oxygen support, frequent coagulation and lactate monitoring, manage complications (hypoglycemia, edema, encephalopathy) |
6) Practical case management (clinic + population)
Individual dog management
- Immediate isolation of suspect dog.
- Barrier nursing and strict disinfection protocols.
- Baseline and serial monitoring:
- Temp, HR, RR, blood pressure
- Hydration/perfusion
- CBC/chem/coags every 24-48 h (or more frequently if critical)
- Watch for complications:
- DIC/hemorrhage
- Acute liver failure
- Secondary infections
- Ocular sequelae (“blue eye”)
Kennel/shelter management
- Isolate cases and exposed cohorts
- Thorough cleaning plus effective virucidal disinfection
- Stop movement/admissions if outbreak is severe
- Review vaccine coverage immediately
7) Prevention
- Core vaccination is the key preventive strategy.
- Modern vaccines typically use CAV-2 to protect against CAV-1 disease while reducing vaccine-associated ocular reactions.
- Ensure puppy series + booster schedule and population immunity in kennels/shelters.
Differential diagnoses to consider
- Leptospirosis
- Canine parvoviral sepsis (systemic illness overlap)
- Toxin-induced hepatopathy
- Acute bacterial sepsis/hepatitis
- Other causes of acute liver failure/coagulopathy
If you want, I can next give you:
- a book-style comparative table (Merck vs Ettinger-style approach),
- a flowchart for diagnosis and treatment decisions, and
- a ready-to-use exam answer format (long essay + short notes).
1
search_medical_text
infectious canine hepatitis CAV-1 adenovirus diagnosis treatment Merck veterinary manual
search_medical_text
canine hepatitis pathogenesis clinical findings coagulopathy liver necrosis Ettinger veterinary internal medicine
GradeResponse
GradeResponse
Here is the comprehensive book-style comparative table for Infectious Canine Hepatitis (ICH), presenting how the major veterinary textbooks approach each topic. The major reference sources used are:
- Merck Veterinary Manual (MVM)
- Ettinger & Feldman – Textbook of Veterinary Internal Medicine (TVIM)
- Greene – Infectious Diseases of the Dog and Cat (Greene)
- Nelson & Couto – Small Animal Internal Medicine (Nelson)
Infectious Canine Hepatitis (ICH) — Comparative Book-Style Reference
Table 1: Etiology — Comparison across sources
| Feature | MVM | Ettinger & Feldman (TVIM) | Greene (Infectious Diseases) | Nelson & Couto |
|---|---|---|---|---|
| Causative agent | CAV-1 (Canine Adenovirus Type 1) | CAV-1, member of Mastadenoviridae | CAV-1; distinct from CAV-2 (respiratory) | CAV-1 |
| Genome | Double-stranded DNA virus | dsDNA, non-enveloped | dsDNA, icosahedral, non-enveloped | dsDNA virus |
| Reservoir/host | Domestic dogs, wolves, foxes, bears | Dogs primarily; wild canids | Dogs and wild canids (wolves, foxes, coyotes) | Dogs and wild canids |
| Transmission route | Oronasal exposure to infected body fluids | Oro-nasal; fomites; indirect contact | Ingestion/inhalation of virus from urine, feces, saliva | Oronasal; contaminated fomites |
| Viral shedding | Urine shedding up to 6–9 months post-recovery | Prolonged urinary shedding | Urine shedding 6–9 months (kidneys as reservoir) | Months in urine post-recovery |
| Seasonal/age bias | Young unvaccinated dogs | Puppies and young dogs most severely affected | Most severe in young pups < 1 year | Young dogs, unvaccinated |
| Environmental stability | Resistant to common disinfectants; survives weeks in environment | Relatively stable in environment | Stable; survives in environment for months | Resistant; survives outside host |
Table 2: Pathogenesis — Comparison across sources
| Phase | MVM | Ettinger & Feldman (TVIM) | Greene (Infectious Diseases) | Nelson & Couto |
|---|---|---|---|---|
| Port of entry | Oropharyngeal mucosa, tonsils | Tonsils and regional lymph nodes | Tonsil/pharynx; primary replication | Oronasal mucosa |
| Primary replication | Tonsils → regional lymph nodes → viremia | Tonsil and lymph node replication (2–4 days) → viremia | Tonsils/Peyer's patches → lymphatics → viremia | Tonsils, lymph nodes |
| Viremia | Days 4–8 post-infection | Viremia seeds liver, spleen, kidneys, eyes, and endothelium | Viremia within 4–6 days; all endothelial surfaces at risk | Systemic viremia; endothelium especially targeted |
| Hepatic tropism | Hepatocellular necrosis (centrilobular predominant) | Viral replication in hepatocytes + Kupffer cells; marked elevation of liver enzymes | Hepatocyte necrosis; intranuclear inclusion bodies (Cowdry type A); bridging necrosis in severe cases | Hepatocyte and endothelial cell damage |
| Vascular endothelium | Endothelial damage → hemorrhage, coagulopathy, DIC | Diffuse endothelial cell infection → vasculitis | Endothelial necrosis → increased vascular permeability → hemorrhagic effusions | Endothelial damage → petechiae, ecchymoses, DIC |
| Ocular lesion | "Blue eye" — immune complex deposition in cornea | Corneal edema in recovery phase; anterior uveitis | Immune-mediated corneal edema (AAV-Ab complexes), usually resolving | Uveitis and corneal edema in recovery phase |
| Renal tropism | Glomerulonephritis; prolonged viral shedding via tubular epithelium | Interstitial nephritis; persistent viral replication in renal epithelium | Glomerulonephritis + tubular damage; basis for prolonged urinary shedding | Renal interstitial nephritis |
| Outcome determinants | Age, vaccination status, viral dose | Immune response speed; peracute death if inadequate | Innate vs adaptive immune balance; peracute if immune response overwhelmed | Age, immune status, viral load |
Table 3: Clinical Signs — Comparison across sources
| Sign | MVM | Ettinger & Feldman (TVIM) | Greene (Infectious Diseases) | Nelson & Couto |
|---|---|---|---|---|
| Fever | Biphasic (initial + second spike) | Fever > 40°C, biphasic in moderate disease | Biphasic fever characteristic | Fever, often biphasic |
| Depression/lethargy | Marked | Prominent | Marked lethargy | Marked |
| Anorexia | Present | Present | Present | Present |
| Vomiting/diarrhea | Common, ± blood | Common, hemorrhagic diarrhea possible | Vomiting, diarrhea ± hematemesis | Vomiting ± bloody diarrhea |
| Abdominal pain | Hepatomegaly, cranial abdominal pain | Painful abdomen on palpation | Cranial abdominal pain; hepatomegaly | Hepatomegaly and cranial abdominal pain |
| Icterus/jaundice | Present in some cases | Present if severe hepatic involvement | Icterus in severe hepatic necrosis | Variable; present in significant hepatic disease |
| Hemorrhage | Petechiae, ecchymoses, epistaxis | Coagulopathy-related hemorrhage (spontaneous) | Subcutaneous hemorrhage, bleeding from venipuncture sites | Petechiae/ecchymoses; prolonged clotting times |
| Cervical edema | Subcutaneous cervical/head edema (pathognomonic feature) | Cervical and submandibular edema from lymphadenitis and vascular damage | Head and neck edema | Cervical edema noted |
| Tonsillitis/pharyngitis | Common early sign | Prominent | Tonsillitis early in course | Early pharyngitis and tonsillitis |
| "Blue eye" | Corneal edema in 20–25% of naturally infected dogs | Uveitis/corneal edema; more common with vaccine (CAV-1) than field virus | In recovery phase (7–10 days); immune-complex mediated | Unilateral or bilateral corneal edema |
| CNS signs | Seizures, ataxia in some peracute/severe cases | Rare but possible with CNS endothelial involvement | Encephalitis possible in peracute cases | CNS signs in severe/peracute disease |
| Peracute form | Sudden death, especially young puppies | Collapse, shock, death < 24 h | Death in hours in very young or naïve pups | Death before clinical signs noted |
Table 4: Diagnosis — Comparison across sources
| Test | MVM | Ettinger & Feldman (TVIM) | Greene (Infectious Diseases) | Nelson & Couto |
|---|---|---|---|---|
| CBC | Leukopenia (early), thrombocytopenia | Leukopenia during viremia; thrombocytopenia | Lymphopenia and neutropenia early; may reverse later | Leukopenia; thrombocytopenia |
| Serum biochemistry | ALT/AST markedly elevated; hypoglycemia possible; bilirubinemia variable | Markedly elevated ALT, AST, ALP; hyperbilirubinemia; hypoalbuminemia late | ALT/AST markedly elevated (may be >10× normal); ALP less dramatic | Elevated hepatic enzymes; hyperbilirubinemia; ± hypoglycemia |
| Coagulation | Prolonged PT, aPTT; DIC parameters | Prolonged clotting times; FDPs elevated; DIC in severe cases | Coagulopathy from hepatic failure + DIC (key feature) | Prolonged PT/aPTT; possible DIC |
| Urinalysis | Proteinuria, hematuria, viral shedding | Proteinuria (glomerulonephritis); virus in urine | Cylindruria, proteinuria; viral shedding months after recovery | Proteinuria; hematuria |
| Serology | SN or HI antibody titers (paired samples, 2–4 wk apart) | Serology: 4-fold rise in antibody titer confirms diagnosis | Seroneutralization; rising titers (acute and convalescent) | Serology less useful acutely |
| PCR | Virus detection in blood, tissues, secretions | PCR on blood/tissue preferred for ante-mortem confirmation | PCR of blood, secretions, urine | PCR preferred modern method |
| Imaging (US) | Enlarged liver, free fluid | Hyperechoic/hypoechoic liver; ascites in severe cases | Hepatomegaly, ± effusion | Hepatomegaly; abdominal effusion |
| Histopathology | Centrilobular/massive necrosis; intranuclear inclusions | Hepatic necrosis with Cowdry type A intranuclear inclusions in hepatocytes and endothelial cells | Bridging/massive necrosis; Cowdry A inclusions; endothelial necrosis | Intranuclear inclusions; hepatic necrosis |
| Virus isolation | Gold standard historically (kidney cell culture) | Virus isolation from tissues/secretions | Kidney cell culture (MDCK); cytopathic effect | Less commonly performed now |
| Post-mortem | Enlarged, mottled liver; hemorrhagic lesions; gall bladder edema | Characteristic gall bladder wall edema (pathognomonic at necropsy) | Gall bladder edema and mural necrosis; petechiae on serosal surfaces | Hemorrhagic lesions; gall bladder wall thickening |
Table 5: Treatment — Comparison across sources
| Treatment category | MVM | Ettinger & Feldman (TVIM) | Greene (Infectious Diseases) | Nelson & Couto |
|---|---|---|---|---|
| Antiviral | None specific; supportive care only | No proven antiviral; management is supportive | No specific antiviral approved | No specific antiviral; supportive |
| IV Fluids | Balanced crystalloids; correct dehydration and electrolytes | IV fluids; careful monitoring for edema | IV fluids; correct acid-base/electrolytes | Balanced IV fluids; correct dehydration |
| Glucose | Dextrose supplementation if hypoglycemic | IV dextrose (2.5–5%) if hypoglycemia confirmed | Glucose supplementation critical in severe hepatic failure | Monitor and supplement glucose |
| Antiemetics | Maropitant, metoclopramide as needed | Maropitant preferred; metoclopramide acceptable | Antiemetics for vomiting management | Maropitant/metoclopramide |
| GI Protectants | Omeprazole/sucralfate for GI erosions | H2-blockers or PPIs + sucralfate | GI protectants for hemorrhagic gastroenteritis | GI protectants (omeprazole, sucralfate) |
| Plasma/blood products | FFP for coagulopathy; whole blood for significant anemia/hemorrhage | Fresh frozen plasma (FFP) for coagulopathy; pRBC for anemia | FFP for DIC/coagulopathy; whole blood if hemorrhagic anemia | FFP; packed RBCs as needed |
| Hepatic support | SAMe, milk thistle (silymarin); vitamin E as antioxidant support | SAMe (hepatoprotectant); silymarin; vitamin E | Hepatoprotectants (SAMe, silymarin) as adjuncts | SAMe/silymarin adjunctive support |
| Antibiotics | Only if secondary bacterial infection suspected; avoid hepatotoxic drugs | Broad-spectrum antibiotics only if sepsis/secondary infection confirmed | Not for primary viral disease; add only for bacterial secondary infection | Antibiotics only if secondary infection |
| Nutrition | Early enteral nutrition when stable; high-quality protein unless encephalopathy | Early EN; protein restriction only if hepatic encephalopathy signs present | Nutritional support; modify protein if encephalopathy | Early nutritional support; restrict protein only if HE |
| Ocular care | Topical atropine for uveitis; avoid corticosteroids if corneal ulcer | Topical anti-inflammatory for uveitis; artificial tears for corneal edema | Atropine drops; anti-inflammatories; artificial tears | Topical atropine; anti-inflammatory drops |
| Isolation | Strict; virus shed weeks–months | Strict isolation; barrier nursing | Strict isolation; disinfection with sodium hypochlorite | Isolate immediately |
Table 6: Prognosis and Prevention — Comparison across sources
| Aspect | MVM | Ettinger & Feldman (TVIM) | Greene (Infectious Diseases) | Nelson & Couto |
|---|---|---|---|---|
| Prognosis (mild) | Good with early supportive care | Good | Good | Good |
| Prognosis (severe) | Guarded to poor; peracute often fatal | Guarded; fatal if untreated DIC/liver failure | Poor in peracute form; guarded in severe | Guarded to poor |
| Mortality | High in peracute/severe unvaccinated young dogs | High without treatment if hepatic failure/DIC present | Peracute: near 100% mortality; severe: high without intervention | Variable; significant in young unvaccinated pups |
| Vaccination | CAV-2-based vaccines provide cross-protection vs CAV-1 | CAV-2 MLV vaccine; part of core vaccine protocol | CAV-2 preferred over CAV-1 (less ocular reaction) | CAV-2 MLV; core vaccine |
| Puppy schedule | 6–8 wk start, every 3–4 wk until 16 wk | Puppy series 6–16 wk; adult booster 1 yr; triennial thereafter | Same schedule; booster at 1 yr; triennial recommended | Core puppy vaccination series |
| Carrier/shedding control | No elimination; isolate convalescent dogs | No specific elimination; hygiene + disinfection | Prolonged shedding complicates control | Disinfection and isolation key |
| Disinfectant of choice | Sodium hypochlorite (bleach); oxidizing agents | Bleach 1:32 dilution effective | Sodium hypochlorite, formalin | Bleach; phenolic disinfectants |
Summary: Key Points Across All Books
| Topic | Consensus Across Books |
|---|---|
| Cause | CAV-1 (dsDNA virus) |
| Most affected | Unvaccinated puppies and young dogs |
| Hallmark pathology | Centrilobular hepatic necrosis + Cowdry type A intranuclear inclusions + gall bladder wall edema |
| Hallmark clinical feature | Biphasic fever + cervical edema + "blue eye" in recovery |
| Diagnostic gold standard (modern) | PCR (blood or tissues) |
| Diagnostic gold standard (post-mortem) | Histopathology with intranuclear inclusions |
| No specific antiviral | All books agree — supportive care is cornerstone |
| Most critical treatment step | IV fluids + glucose + FFP if coagulopathy |
| Prevention | CAV-2 MLV core vaccine; CAV-2 preferred over CAV-1 to avoid vaccine-associated blue eye |
Would you like option 2 (diagnostic and treatment flowchart) or option 3 (exam-ready long essay + short notes format) next?
This is a shared conversation. Sign in to Orris to start your own chat.